The medical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s demonstrating significant efficacy in clinical trials for addressing obesity. Unlike some current weight loss treatments, retatrutide appears to offer a more substantial loss in bo